IMMUCELL CORP - 10-Q Summary (Period Ended Sept 30, 1995)
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for ImmuCell Corporation for the three and nine-month periods ended September 30, 1995. The company is a biotechnology firm focused on developing passive antibody products to prevent gastrointestinal diseases, including diarrhea in AIDS patients and travelers' diarrhea. The company operates with a wholly-owned subsidiary, Kamar Marketing Group, Inc.
Key Financial Metrics
| Metric | 9 Months Ended Sept 30, 1995 | 9 Months Ended Sept 30, 1994 | 3 Months Ended Sept 30, 1995 | 3 Months Ended Sept 30, 1994 |
|---|---|---|---|---|
| Total Revenues | $3,807,875 | $3,363,238 | $1,175,651 | $1,096,706 |
| Product Sales | $3,373,193 | $2,975,133 | $989,598 | $958,601 |
| Grant Income | $434,682 | $138,105 | $186,053 | $138,105 |
| Net Loss | $(21,100) | $(91,517) | $(10,118) | $(29,469) |
| Net Loss Per Share | $(0.01) | $(0.03) | -- | $(0.01) |
| Cash & Equivalents (End of Period) | $1,001,920 | $1,404,476 | $1,001,920 | $1,404,476 |
| Short-Term Investments | $463,536 | -- | $463,536 | -- |
| Total Debt (Current + Long Term) | $1,311,686 | $1,199,144 | $1,311,686 | $1,199,144 |
| Working Capital | $1,907,419 | $1,727,525 | $1,907,419 | $1,727,525 |
Product Gross Margin: Improved to 55% for the nine months ended Sept 30, 1995, compared to 50% in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 13% year-over-year for the nine-month period, driven by a 13% increase in product sales and a significant rise in grant income ($435k vs $138k).
- Loss Reduction: Net loss improved significantly, decreasing from $91,517 in the prior year nine-month period to $21,100 in the current period.
- Revenue Composition: Collaborative research revenue of $250,000 recognized in 1994 (from Univax Biologics) was absent in 1995 following the termination of that partnership in May 1995. ImmuCell reacquired marketing rights to the CRYPTOGAM product and is now funding its Phase I/II trials internally.
- Expense Increases: Research and development (R&D) expenses increased 21% to $1.235 million for the nine-month period, primarily due to clinical trial costs and development of new antibody products. Sales and marketing expenses rose 10%.
- Liquidity: While cash and cash equivalents decreased by approximately $293,000 during the nine months, the company increased its liquid position by adding $463,536 in short-term investments. Working capital increased by approximately $180,000.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur further operating losses as it aggressively invests in R&D to develop products preventing gastrointestinal diseases. The strategy involves demonstrating efficacy in clinical trials to attract corporate partners for funding and marketing rights.
- Capital Resources: The company believes it has sufficient capital to meet working capital requirements for the next 12 months. Approximately $417,000 in grant funds remains available for future expenditures.
- Debt Financing: In September 1995, the company secured a new $200,000 note payable at 9.62% interest to repay a second mortgage and fund manufacturing equipment and building improvements.
- Contingencies: To maintain an exclusive worldwide license for a milk purification system, the company must purchase a commercial-size system in 1996. Management is seeking a partner to fund this purchase; otherwise, the company may need to fund it internally.
- Risks: Continued reliance on grant funding and the ability to secure corporate partners for product commercialization are critical risks. The company is currently funding the CRYPTOGAM clinical trial internally after losing its previous partner.
Key Facts for Investor Verification
- Grant Dependency: Verify the status and future funding certainty of the three NIAID SBIR grants totaling $1,035,000, which funded a significant portion of recent R&D.
- Partnership Status: Confirm the company's progress in securing a new corporate partner to fund the commercialization of the CRYPTOGAM product and the milk purification system.
- Cash Burn Rate: Monitor the net cash used in operating activities versus the remaining grant funds ($417,000) to assess runway without additional financing.
- Debt Covenants: Review the terms of the new $200,000 note and existing debt obligations to ensure compliance with covenants, particularly regarding the purchase of the commercial purification system in 1996.
- Product Mix: Verify the sustainability of the improved gross margin (55%), which was driven by increased sales of immunoreagents with lower costs of sales.